-
1.发明申请TREATMENT OF PATHOLOGIES WHICH ESCAPE THE IMMUNE RESPONSE, USING OPTIMIZED ANTIBODIES 审中-公开使用优化抗体治疗免疫应答的病理学治疗公开(公告)号：US20090081216A1
公开(公告)日：2009-03-26
申请号：US12234609
申请日：2008-09-19
IPC分类号： A61K39/395
CPC分类号： C07K16/2833 , C07K16/2896 , C07K16/34 , C07K2317/732
摘要： The invention relates to the use of potimised human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies having a strong affvinity for receptor CD16 of the effector cells of the immune system and being able to induce the secretion of cytokines and interleukins, in particular 1“IFN? Or 1” IL2, for the treatment of pathologies for which the target cells only express a low antigenic density and in which the effector cells can only be recruited in small quantities.
摘要翻译： 本发明涉及在所选择的细胞系中产生的人体或人源化嵌合单克隆抗体的用途，所述抗体对免疫系统的效应细胞的受体CD16具有很强的亲和性，并能够诱导细胞因子和白介素的分泌 ，特别是1“IFNα或1”IL2，用于治疗目标细胞仅表达低抗原密度并且其中仅能够少量招募效应细胞的病理学。
-
公开(公告)号：US20100145026A1
公开(公告)日：2010-06-10
申请号：US12576202
申请日：2009-10-08
IPC分类号： C07K16/00
CPC分类号： C07K16/2833 , A61K2039/505 , C07K2317/41 , C07K2317/732
摘要： The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFNγ, which can enhance the ADCC activity of effector cells and hence be used for treating cancers and infections by pathogenic agents.
摘要翻译： 本发明涉及在选择的细胞系中产生的人源化或人类的嵌合单克隆抗体，所述抗体对免疫系统的效应细胞的CD16受体表现出高亲和力，因此能够诱导高ADCC，而且还诱导诱导细胞因子和白介素分泌的性质 ，特别是IFNγ，其可以增强效应细胞的ADCC活性，因此可用于治疗癌症和病原体感染。
-
搜索结果
2 条记录 (耗时 0.017 秒)
